PT1601670E - Compostos de arilvinilazacicloalcano e métodos para a sua preparação e utilização - Google Patents

Compostos de arilvinilazacicloalcano e métodos para a sua preparação e utilização Download PDF

Info

Publication number
PT1601670E
PT1601670E PT04717398T PT04717398T PT1601670E PT 1601670 E PT1601670 E PT 1601670E PT 04717398 T PT04717398 T PT 04717398T PT 04717398 T PT04717398 T PT 04717398T PT 1601670 E PT1601670 E PT 1601670E
Authority
PT
Portugal
Prior art keywords
preparation
methods
arylvinylazacycloalkane
compounds
arylvinylazacycloalkane compounds
Prior art date
Application number
PT04717398T
Other languages
English (en)
Portuguese (pt)
Inventor
Michel Cheve
Arielle Genevois-Borella
Marc Capet
Jeffrey Daniel Schmitt
Gary Maurice Dull
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of PT1601670E publication Critical patent/PT1601670E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT04717398T 2003-03-05 2004-03-04 Compostos de arilvinilazacicloalcano e métodos para a sua preparação e utilização PT1601670E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/379,868 US7098331B2 (en) 2003-03-05 2003-03-05 Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
PT1601670E true PT1601670E (pt) 2008-07-11

Family

ID=32926772

Family Applications (2)

Application Number Title Priority Date Filing Date
PT04717398T PT1601670E (pt) 2003-03-05 2004-03-04 Compostos de arilvinilazacicloalcano e métodos para a sua preparação e utilização
PT09075124T PT2085395E (pt) 2003-03-05 2004-03-04 Compostos de arilvinilazacicloalcano e métodos para a sua preparação e utilização

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT09075124T PT2085395E (pt) 2003-03-05 2004-03-04 Compostos de arilvinilazacicloalcano e métodos para a sua preparação e utilização

Country Status (31)

Country Link
US (8) US7098331B2 (enExample)
EP (3) EP2085395B1 (enExample)
JP (3) JP4663627B2 (enExample)
KR (4) KR20120014236A (enExample)
CN (3) CN101550132B (enExample)
AR (3) AR043469A1 (enExample)
AT (3) ATE496046T1 (enExample)
AU (3) AU2004217903B2 (enExample)
BR (1) BRPI0409576A (enExample)
CA (1) CA2516514C (enExample)
CL (1) CL2004000452A1 (enExample)
CY (2) CY1110391T1 (enExample)
DE (2) DE602004031165D1 (enExample)
DK (2) DK2085395T3 (enExample)
EA (3) EA010870B1 (enExample)
ES (3) ES2309507T3 (enExample)
GT (1) GT200400033A (enExample)
IL (3) IL170155A (enExample)
JO (1) JO2488B1 (enExample)
MX (1) MXPA05009386A (enExample)
NO (3) NO331920B1 (enExample)
NZ (1) NZ541795A (enExample)
PA (1) PA8597201A1 (enExample)
PE (1) PE20040930A1 (enExample)
PL (5) PL2085395T3 (enExample)
PT (2) PT1601670E (enExample)
SI (2) SI1601670T1 (enExample)
TW (3) TW200927746A (enExample)
UY (1) UY28218A1 (enExample)
WO (1) WO2004078752A1 (enExample)
ZA (1) ZA200506790B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
FR2896800B1 (fr) * 2006-01-30 2008-04-11 Servier Lab Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
WO2009140201A1 (en) * 2008-05-12 2009-11-19 Targacept, Inc. Methods for preventing the development of retinopathy by the oral administration of nnr ligands
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
DK3279195T3 (en) 2008-12-01 2020-08-17 Oyster Point Pharma Inc Synthesis and novel salt forms of (R)-5-((E)-2-(pyrrolidin-3-ylvinyl)pyrimidine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
AU2010260265A1 (en) * 2009-06-17 2011-12-22 Targacept, Inc. Reversal of L-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
SG181109A1 (en) 2009-12-07 2012-07-30 Targacept Inc 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
CN102858342B (zh) * 2010-03-11 2014-12-10 塔加西普特公司 用于便秘的芳基乙烯基氮杂环烷烃化合物
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20140081714A1 (en) * 2012-09-19 2014-03-20 Salesforce.Com, Inc. Systems and methods of rewarding users in an on-demand system
US20140278929A1 (en) * 2013-03-15 2014-09-18 Yahoo! Inc. System and method identifying opportunities for advertising entities based on user goal achievement
US10709707B2 (en) 2016-04-07 2020-07-14 Oyster Point Pharma, Inc. Methods of treating ocular conditions
KR101848601B1 (ko) * 2016-07-27 2018-04-12 송기봉 일회용 위생 티슈
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
EP4142734B1 (en) 2020-04-28 2025-08-20 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
DK1027336T3 (da) 1997-10-27 2005-01-24 Neurosearch As Heteroaryldiazacycloalkaner, deres fremstilling og anvendelse
CA2376061A1 (en) 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
MXPA02002115A (es) 1999-09-14 2002-10-31 Abbott Lab Compuestos de eter 3-pirrolidiniloxi-3'-piridilico, utiles para controlar la transmision sinaptica quimica. .
AU780492B2 (en) 1999-11-01 2005-03-24 Targacept, Inc. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
US6624167B1 (en) * 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
US6881738B2 (en) 2001-07-19 2005-04-19 Medical College Of Georgia Research Institute Analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Also Published As

Publication number Publication date
CA2516514A1 (en) 2004-09-16
TWI377204B (en) 2012-11-21
CL2004000452A1 (es) 2005-05-20
JP2006519868A (ja) 2006-08-31
US20110152293A1 (en) 2011-06-23
AR070569A2 (es) 2010-04-21
NO332293B1 (no) 2012-08-20
US20140107164A1 (en) 2014-04-17
CN101550132B (zh) 2012-03-28
BRPI0409576A (pt) 2006-04-18
EA014714B1 (ru) 2011-02-28
US20100010042A1 (en) 2010-01-14
CN101550132A (zh) 2009-10-07
JP5537084B2 (ja) 2014-07-02
JP4663627B2 (ja) 2011-04-06
KR20090021227A (ko) 2009-02-27
NZ541795A (en) 2008-03-28
NO20091888L (no) 2005-10-03
EP1601670B1 (en) 2008-05-07
JP5537085B2 (ja) 2014-07-02
SI1601670T1 (sl) 2008-10-31
NO20054120D0 (no) 2005-09-05
AR070570A2 (es) 2010-04-21
PL378415A1 (pl) 2006-04-03
US20150164894A1 (en) 2015-06-18
EA200900706A1 (ru) 2009-10-30
AU2008258188B2 (en) 2011-02-24
WO2004078752A1 (en) 2004-09-16
CY1110391T1 (el) 2015-04-29
US8063068B2 (en) 2011-11-22
JP2009292825A (ja) 2009-12-17
AU2004217903A1 (en) 2004-09-16
IL197889A (en) 2013-03-24
UY28218A1 (es) 2005-06-30
AR043469A1 (es) 2005-07-27
US20080293778A1 (en) 2008-11-27
TW200505909A (en) 2005-02-16
CA2516514C (en) 2012-02-07
NO20054120L (no) 2005-10-03
US7098331B2 (en) 2006-08-29
ZA200506790B (en) 2006-05-31
IL170155A (en) 2013-08-29
EA200801764A1 (ru) 2008-12-30
EP1947100A1 (en) 2008-07-23
ATE394394T1 (de) 2008-05-15
MXPA05009386A (es) 2005-11-04
CN101255155A (zh) 2008-09-03
PL215059B1 (pl) 2013-10-31
EP1947100B1 (en) 2011-07-27
HK1084949A1 (en) 2006-08-11
NO20092231L (no) 2005-10-03
HK1116800A1 (en) 2009-01-02
JP2010001296A (ja) 2010-01-07
KR20060006006A (ko) 2006-01-18
DE602004031165D1 (de) 2011-03-03
KR101018083B1 (ko) 2011-03-02
ATE517893T1 (de) 2011-08-15
US20060094732A1 (en) 2006-05-04
AU2004217903B2 (en) 2010-03-04
PE20040930A1 (es) 2005-02-18
SI2085395T1 (sl) 2011-05-31
ES2309507T3 (es) 2008-12-16
US7714001B2 (en) 2010-05-11
CY1111615T1 (el) 2015-10-07
AU2008258187A1 (en) 2009-01-15
PL394600A1 (pl) 2011-07-18
TWI339662B (en) 2011-04-01
PL216979B1 (pl) 2014-06-30
KR101185541B1 (ko) 2012-09-24
IL197890A (en) 2013-11-28
EP2085395A1 (en) 2009-08-05
GT200400033A (es) 2005-05-29
CN1756754A (zh) 2006-04-05
ES2385941T3 (es) 2012-08-03
CN100526308C (zh) 2009-08-12
US8633222B2 (en) 2014-01-21
EP1601670A1 (en) 2005-12-07
DE602004013553D1 (de) 2008-06-19
PL394604A1 (pl) 2011-07-18
EA200501425A1 (ru) 2006-02-24
US20100267776A1 (en) 2010-10-21
PL1601670T3 (pl) 2008-10-31
DK1601670T3 (da) 2008-08-25
EA019240B1 (ru) 2014-02-28
EP2085395B1 (en) 2011-01-19
EA010870B1 (ru) 2008-12-30
ES2389106T3 (es) 2012-10-23
US8067443B2 (en) 2011-11-29
TW200927746A (en) 2009-07-01
JO2488B1 (en) 2009-10-05
AU2008258188A1 (en) 2009-01-15
NO331920B1 (no) 2012-04-30
US20040176348A1 (en) 2004-09-09
TW200927745A (en) 2009-07-01
KR100953150B1 (ko) 2010-04-19
ATE496046T1 (de) 2011-02-15
KR20090021228A (ko) 2009-02-27
AU2008258187B2 (en) 2010-08-05
KR20120014236A (ko) 2012-02-16
HK1130254A1 (en) 2009-12-24
PT2085395E (pt) 2011-04-20
DK2085395T3 (da) 2011-04-18
PA8597201A1 (es) 2004-09-28
PL2085395T3 (pl) 2011-05-31

Similar Documents

Publication Publication Date Title
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
IL176958A0 (en) Compounds and methods of use
IL172689A0 (en) Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE
PL378294A1 (pl) Pochodne izochinolinowe i sposoby ich stosowania
AU2003259735A8 (en) Small-mer compositions and methods of use
ZA200600387B (en) Hydrolytically-resistant bornon-containing therapeutics and methods of use
AU2003225669A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003225668A1 (en) Pin1-modulating compounds and methods of use thereof
IL182734A0 (en) 4-aminotetracyclines and methods of use thereof
GB0325192D0 (en) Method of use
PL378331A1 (pl) Tetracykliczne pochodne benzamidowe i sposoby ich stosowania
TWI339662B (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
IL169648A0 (en) Novel structures and method of preparation
AU2003299441A8 (en) Nf-hev compositions and methods of use
EP1638565A4 (en) SUBSTITUTED PIPERIDINE COMPOUNDS AND METHOD OF USE THEREOF
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
EP1633850A4 (en) OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE
GB0304555D0 (en) Compounds and methods of manufacture
GB0300805D0 (en) Compounds and their use
GB0300804D0 (en) Compounds and their use
AU2003298725A8 (en) Preparation of metallotexaphyrins
EP1697349A4 (en) DOXEPINE ANALOGUES AND METHODS OF USE
GB0301143D0 (en) Compounds and their use
AU2003267944A8 (en) Novel trifluoromethylepinephrine compounds and methods of making and using thereof